Advertisement

Chimeric RNA pp 125-139 | Cite as

NanoString nCounter Technology: High-Throughput RNA Validation

  • Angela GoytainEmail author
  • Tony Ng
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 2079)

Abstract

NanoString nCounter is a multiplex nucleic acid hybridization technology that enables reliable and reproducible assessment of the expression of up to 800 genes or 228 gene fusions in 12 samples in a single assay. The technique works well with a variety of starting materials from fresh or formalin-fixed tissues, cell lysates or biological fluid samples. As low as 1 ng RNA input per sample is needed. In addition to gene expression, copy number variation, single nucleotide variation and chimeric RNAs can be analyzed. In this chapter, we discuss the design, setup, and performance of a NanoString-based RNA assay for gene expression or fusion transcript assessment.

Key words

NanoString nCounter RNA DNA Gene expression Chimeric RNA Probe hybridization Molecular barcode 

References

  1. 1.
    NanoString Technologies (2003) https://www.NanoString.com/. Accessed January 2019
  2. 2.
    Wallden B, Storhoff J, Nielsen T, Dowidar N et al (2015) Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med Genet 8:54–68.  https://doi.org/10.1186/s12920-015-0129-6CrossRefGoogle Scholar
  3. 3.
    Lira ME, Choi YL, Lim SM, Deng S et al (2014) A single-tube multiplex assay for detecting ALK, ROS1, and RET fusions in lung cancer. J Mol Diagn 16(2):229–243.  https://doi.org/10.1016/j.jmoldx.2013.11.007CrossRefPubMedGoogle Scholar
  4. 4.
    Hu D, Zhou W, Wang F, Shu SM et al (2016) Development of a NanoString assay to detect leukemogenic fusion transcripts in acute myeloid leukemia. Int J Lab Hematol 38(6):663–673.  https://doi.org/10.1111/ijlh.12555CrossRefPubMedGoogle Scholar
  5. 5.
    Scott DW, Abrisqueta P, Wright GW, Slack GW et al (2017) New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies. J Clin Oncol 35(15):1668–1677.  https://doi.org/10.1200/JCO.2016.70.7901CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Chang KTE, Goytain A, Tucker T, Karsan A et al (2018) Development and evaluation of a Pan-Sarcoma fusion gene detection assay using the NanoString nCounter platform. J Mol Diagn 20(1):63–77.  https://doi.org/10.1016/j.jmoldx.2017.09.007CrossRefPubMedGoogle Scholar
  7. 7.
    Geiss GK, Bumgardner RE, Birditt B, Dahl T et al (2008) Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 26(3):317–326CrossRefGoogle Scholar
  8. 8.
    Parker JS, Mullins M, Cheang MC et al (2009) Supervised risk factor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160–1167CrossRefGoogle Scholar
  9. 9.
    Veldman-Jones MH, Brant R, Rooney C et al (2015) Evaluating robustness and sensitivity of the NanoString technologies nCounter platform to enable multiplexed gene expression analysis of clinical samples. Cancer Res 75(13):2587–2593.  https://doi.org/10.1158/0008-5472.CAN-15-0262CrossRefPubMedGoogle Scholar
  10. 10.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Department of PathologyUniversity of British ColumbiaVancouverCanada
  2. 2.Jack Bell Research CentreVancouverCanada
  3. 3.Department of PathologyBritish Columbia Cancer AgencyVancouverCanada
  4. 4.Department of PathologyVancouver General HospitalVancouverCanada

Personalised recommendations